BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

433 related articles for article (PubMed ID: 18319586)

  • 1. Inhaled corticosteroids as additional treatment in alpha-1-antitrypsin-deficiency-related COPD.
    Corda L; Bertella E; La Piana GE; Boni E; Redolfi S; Tantucci C
    Respiration; 2008; 76(1):61-8. PubMed ID: 18319586
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A double-blind crossover study comparing the safety and efficacy of three weeks of Flu/Sal 250/50 bid plus albuterol 180 ug prn q4 hours to Flu/Sal 250/50 bid plus albuterol/Ipratropium bromide 2 puffs prn q4 hours in patients with chronic obstructive pulmonary disease.
    Balkissoon R; Make B
    COPD; 2008 Aug; 5(4):221-7. PubMed ID: 18671147
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Benefits and risks of adjunctive inhaled corticosteroids in chronic obstructive pulmonary disease: a meta-analysis.
    Sobieraj DM; White CM; Coleman CI
    Clin Ther; 2008 Aug; 30(8):1416-25. PubMed ID: 18803985
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effect of bronchodilators and oxygen alone and in combination on self-paced exercise performance in stable COPD.
    Cukier A; Ferreira CA; Stelmach R; Ribeiro M; Cortopassi F; Calverley PM
    Respir Med; 2007 Apr; 101(4):746-53. PubMed ID: 17000096
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Survival among COPD patients using fluticasone/salmeterol in combination versus other inhaled steroids and bronchodilators alone.
    Mapel DW; Nelson LS; Lydick E; Soriano J; Yood MU; Davis KJ
    COPD; 2007 Jun; 4(2):127-34. PubMed ID: 17530506
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fast onset of effect of budesonide/formoterol versus salmeterol/fluticasone and salbutamol in patients with chronic obstructive pulmonary disease and reversible airway obstruction.
    Lindberg A; Szalai Z; Pullerits T; Radeczky E
    Respirology; 2007 Sep; 12(5):732-9. PubMed ID: 17875063
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Withdrawal of fluticasone propionate from combined salmeterol/fluticasone treatment in patients with COPD causes immediate and sustained disease deterioration: a randomised controlled trial.
    Wouters EF; Postma DS; Fokkens B; Hop WC; Prins J; Kuipers AF; Pasma HR; Hensing CA; Creutzberg EC;
    Thorax; 2005 Jun; 60(6):480-7. PubMed ID: 15923248
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mono- and combination therapy of long-acting bronchodilators and inhaled corticosteroids in advanced COPD.
    Ohar JA; Donohue JF
    Semin Respir Crit Care Med; 2010 Jun; 31(3):321-33. PubMed ID: 20496301
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of inhaled HFA beclomethasone on pulmonary function and symptoms in patients with chronic obstructive pulmonary disease.
    John M; Bosse S; Oltmanns U; Schumacher A; Witt C
    Respir Med; 2005 Nov; 99(11):1418-24. PubMed ID: 15894479
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An evaluation of salmeterol in the treatment of chronic obstructive pulmonary diseases.
    Gupta RK; Chhabra SK
    Indian J Chest Dis Allied Sci; 2002; 44(3):165-72. PubMed ID: 12206475
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of combination treatment on lung volumes and exercise endurance time in COPD.
    Magnussen H; Paggiaro P; Schmidt H; Kesten S; Metzdorf N; Maltais F
    Respir Med; 2012 Oct; 106(10):1413-20. PubMed ID: 22749044
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of acute bronchodilator reversibility in patients with symptoms of GOLD stage I COPD.
    O'Donnell DE; Laveneziana P; Ora J; Webb KA; Lam YM; Ofir D
    Thorax; 2009 Mar; 64(3):216-23. PubMed ID: 19052054
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of tiotropium or combined therapy with salmeterol on hyperinflation in COPD.
    Eguchi Y; Tateishi Y; Umeda N; Yoshikawa T; Kamoi H; Kanazawa H; Kudoh S; Hirata K; Fujimoto S
    Osaka City Med J; 2007 Jun; 53(1):25-34. PubMed ID: 17867631
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Improved respiratory system conductance following bronchodilator predicts reduced exertional dyspnoea.
    Diba C; King GG; Berend N; Salome CM
    Respir Med; 2011 Sep; 105(9):1345-51. PubMed ID: 21482091
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enhanced persistence with tiotropium compared with other respiratory drugs in COPD.
    Breekveldt-Postma NS; Koerselman J; Erkens JA; Lammers JW; Herings RM
    Respir Med; 2007 Jul; 101(7):1398-405. PubMed ID: 17368011
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Additive effects of transdermal tulobuterol to inhaled tiotropium in patients with COPD.
    Ichinose M; Seyama K; Nishimura M; Fukuchi Y; Nagai A; Mishima M; Kubo K;
    Respir Med; 2010 Feb; 104(2):267-74. PubMed ID: 19875277
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of salmeterol on sleeping oxygen saturation in chronic obstructive pulmonary disease.
    Ryan S; Doherty LS; Rock C; Nolan GM; McNicholas WT
    Respiration; 2010; 79(6):475-81. PubMed ID: 19684384
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The influence of treatment with formoterol, formoterol with tiotropium, formoterol with inhaled glucocorticosteroid and tiotropium on lung functions, tolerance of exercise and simple, morning everyday activities in patients with chronic obstructive pulmonary disease (COPD)].
    Szmidt M
    Pneumonol Alergol Pol; 2012; 80(3):255-62. PubMed ID: 22562275
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combining tiotropium and salmeterol in COPD: Effects on airflow obstruction and symptoms.
    van Noord JA; Aumann JL; Janssens E; Smeets JJ; Zaagsma J; Mueller A; Cornelissen PJ
    Respir Med; 2010 Jul; 104(7):995-1004. PubMed ID: 20303247
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combining triple therapy and pulmonary rehabilitation in patients with advanced COPD: a pilot study.
    Pasqua F; Biscione G; Crigna G; Auciello L; Cazzola M
    Respir Med; 2010 Mar; 104(3):412-7. PubMed ID: 19892540
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.